Clareo Health | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women, between the ages of 18 and 55
Diagnosis of SLE
Have had a disease duration of at least 1 year, as diagnosed by a physician
You may not be if
Have a disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of SLE) that would interfere with the study evaluation, completion and/or procedures per the investigator's discretion
Have active vasculitis, active CNS lupus requiring therapy, active acute renal disease, uncontrolled hypertension, uncontrolled diabetes or active systemic infection
Have had signs or symptoms of viral or bacterial infection within 30 days of enrollment
Have received a daily dose of greater than 10 mg prednisone (or equivalent) in the prior 30 days
